Literature DB >> 26017397

Thromboembolic resolution assessed by CT pulmonary angiography after treatment for acute pulmonary embolism.

Paul L den Exter1, Josien van Es, Lucia J M Kroft, Petra M G Erkens, Renée A Douma, Inge C M Mos, Gé Jonkers, Marcel M C Hovens, Marc F Durian, Hugo ten Cate, Ludo F M Beenen, Pieter Willem Kamphuisen, Menno V Huisman.   

Abstract

The systematic assessment of residual thromboembolic obstruction after treatment for acute pulmonary embolism (PE) has been understudied. This assessment is of potential clinical importance, should clinically suspected recurrent PE occur, or as tool for risk stratification of cardiopulmonary complications or recurrent venous thromboembolism (VTE). This study aimed to assess the rate of PE resolution and its implications for clinical outcome. In this prospective, multi-center cohort study, 157 patients with acute PE diagnosed by CT pulmonary angiography (CTPA) underwent follow-up CTPA-imaging after six months of anticoagulant treatment. Two expert thoracic radiologists independently assessed the presence of residual thromboembolic obstruction. The degree of obstruction at baseline and follow-up was calculated using the Qanadli obstruction index. All patients were followed-up for 2.5 years. At baseline, the median obstruction index was 27.5 %. After six months of treatment, complete PE resolution had occurred in 84.1 % of the patients (95 % confidence interval (CI): 77.4-89.4 %). The median obstruction index of the 25 patients with residual thrombotic obstruction was 5.0 %. During follow-up, 16 (10.2 %) patients experienced recurrent VTE. The presence of residual thromboembolic obstruction was not associated with recurrent VTE (adjusted hazard ratio: 0.92; 95 % CI: 0.2-4.1).This study indicates that the incidence of residual thrombotic obstruction following treatment for PE is considerably lower than currently anticipated. These findings, combined with the absence of a correlation between residual thrombotic obstruction and recurrent VTE, do not support the routine use of follow-up CTPA-imaging in patients treated for acute PE.

Entities:  

Keywords:  Pulmonary arteries; multidetector computed tomography; pulmonary circulation; pulmonary embolism

Mesh:

Substances:

Year:  2015        PMID: 26017397     DOI: 10.1160/TH14-10-0842

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  14 in total

1.  Incidence of residual perfusion defects by lung scintigraphy in patients treated with rivaroxaban compared with warfarin for acute pulmonary embolism.

Authors:  Ming Sheng Lim; Dee Nandurkar; Ian Jong; Anita Cummins; Huyen Tran; Sanjeev Chunilal
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

Review 2.  Thrombotic complications in patients with cancer: Advances in pathogenesis, prevention, and treatment-A report from ICTHIC 2021.

Authors:  Anna Falanga; Benjamin Brenner; Alok A Khorana; Charles W Francis
Journal:  Res Pract Thromb Haemost       Date:  2022-07-01

3.  Factors associating with the presence of residual thrombosis after 3-month treatment of acute pulmonary embolism.

Authors:  Jingluan Wang; Mingling Xu; Nina Sun; Zhaozhong Cheng; Jingjing Sui
Journal:  J Thromb Thrombolysis       Date:  2018-01       Impact factor: 2.300

4.  ANMCO Position Paper: long-term follow-up of patients with pulmonary thromboembolism.

Authors:  Carlo D'Agostino; Pietro Zonzin; Iolanda Enea; Michele Massimo Gulizia; Walter Ageno; Piergiuseppe Agostoni; Michele Azzarito; Cecilia Becattini; Amedeo Bongarzoni; Francesca Bux; Franco Casazza; Nicoletta Corrieri; Michele D'Alto; Nicola D'Amato; Andrea Maria D'Armini; Maria Grazia De Natale; Giovanni Di Minno; Giuseppe Favretto; Lucia Filippi; Valentina Grazioli; Gualtiero Palareti; Raffaele Pesavento; Loris Roncon; Laura Scelsi; Antonella Tufano
Journal:  Eur Heart J Suppl       Date:  2017-05-02       Impact factor: 1.803

5.  Association between computed tomography obstruction index and mortality in elderly patients with acute pulmonary embolism: A prospective validation study.

Authors:  Marie Méan; Tobias Tritschler; Andreas Limacher; Stéphane Breault; Nicolas Rodondi; Drahomir Aujesky; Salah D Qanadli
Journal:  PLoS One       Date:  2017-06-08       Impact factor: 3.240

6.  Factors determining altered perfusion after acute pulmonary embolism assessed by quantified single-photon emission computed tomography-perfusion scan.

Authors:  Marc Meysman; Hendrik Everaert; Walter Vincken
Journal:  Ann Thorac Med       Date:  2017 Jan-Mar       Impact factor: 2.219

Review 7.  Predicting the Risk of Recurrent Venous Thromboembolism: Current Challenges and Future Opportunities.

Authors:  Hannah Stevens; Karlheinz Peter; Huyen Tran; James McFadyen
Journal:  J Clin Med       Date:  2020-05-22       Impact factor: 4.241

8.  Resolution of acute pulmonary embolism using anticoagulation therapy alone in coronavirus disease 2019.

Authors:  Charles A Ritchie; Margaret M Johnson; Justin T Stowell; Hajra Idrees; Beau Toskich; Ricardo Paz-Fumagalli; Seyed Montazeri; Susana Fortich; Camila Franco-Mesa; Peter Gloviczki; Haraldur Bjarnason; Candido Rivera; Marwan Shaikh; Pablo Moreno-Franco; Devang Sanghavi; Christopher P Marquez; Robert D McBane; Myung S Park; John C O'Horo; James F Meschia; Young Erben
Journal:  J Vasc Surg Venous Lymphat Disord       Date:  2022-01-25

9.  Serial imaging after pulmonary embolism and correlation with functional limitation at 12 months: Results of the ELOPE Study.

Authors:  Kim A Ma; Susan R Kahn; Arash Akaberi; Carole Dennie; Christopher Rush; John T Granton; David Anderson; Philip S Wells; Marc A Rodger; Susan Solymoss; Michael J Kovacs; Lawrence Rudski; Avi Shimony; Paul Hernandez; Shawn D Aaron; Elena Pena; Gad Abikhzer; Andrew M Hirsch
Journal:  Res Pract Thromb Haemost       Date:  2018-06-17

10.  Comparison between CT and MRI in the assessment of pulmonary embolism: A meta-analysis.

Authors:  Feng Chen; Yi-Hong Shen; Xu-Qing Zhu; Jing Zheng; Feng-Jie Wu
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.